Of the 18 companies, only six companies have been given the coveted status of ‘buy’. These are Aurobindo Pharma (TP Rs. 1,293), Cadila (TP Rs. 1,636), Indoco Remedies (TP Rs. 392), JB Chemicals (TP Rs. 295), Dr Reddy (TP Rs. 3,581) and Lupin (TP Rs. 1,710).
Several of Daljeet’s all-time favourite stocks like Ajanta Pharma, Alembic Pharma and Shilpa Medicare have been put on the bench with a ‘hold’ rating. Daljeet has made it clear that he is bullish about the fundamentals of these stocks but is jittery about their near-time valuations.
Surprisingly, even IPCA Labs, which is in the dog-house at present, has been put on hold. Clearly, Daljeet is not inclined to be a contrarian.
One stock, Jubilant LifeSciences, has been condemned with a ‘sell’ rating.
Overall, Daljeet is gung-ho about the Pharma sector. He says the stocks will show on an average sales and profit growth of 18.1% and 13.9% respectively on a YOY basis.